Hi there, we see you're using OS, why not try our app?
Our Strategic Plan 2015-20: Improving outcomes for patients and donors
Our strategy sets out an innovative and translational research programme which, through strong academic partnerships based around our unique capabilities, continues to deliver improvements in donor care and patient outcomes.
Our strategic goals build upon these strengths and will ensure that our research programme is world-leading and continues to bring about changes in patient and donor care. Please click below for more information about each goal.
Working with the Directors of the NIHR BTRUs, we will support delivery of the objectives of each of these ambitious research units and the translation of their outputs into clinical practice.
Working in partnership with Public Health England we will focus on hepatitis E (HEV) and hepatitis B (HBV) during the early years of this strategy, with a focus on emerging infections throughout, in order to maintain transfusion and transplant safety.
We will complete ongoing studies focused on the appropriate use of platelets and red cells in the multi-transfused, neonates, and patients with low platelet counts.
We will conduct a clinical trial on patients requiring coagulation replacement; this was identified as a priority by the Patient Blood Management strategy group.
We will conduct a first-in-man clinical trial of manufactured red cells to compare the survival of red cells manufactured from stem cells with that of standard red cells from blood donors.
We will continue to support pre-clinical science on manufactured red cells and platelets with cell biology research to understand how stem cells turn into blood cells.
We will establish a Donor Behaviour research strategy group across blood, tissues and organs that will develop a programme of research in behavioural change interventions.
We will prioritise behavioural change interventions which could have a positive impact on organ donation and utilisation rates in support of the Taking Organ Transplantation to 2020 strategy.
We will develop a Translational Data Science function by investing in people with the relevant quantitative interdisciplinary expertise for building and exploiting big data resources for donor and patient benefit.
We will prioritise and deliver studies using these unique linkages e.g. applying genomics data to donor management and the identification of donor factors which predict component storage characteristics and post-treatment effects of transfusions and transplants.
We will work with our academic partners to ensure that our scientists and clinicians are embedded within environments which facilitate the successful delivery of innovative research programmes.
We will continue the practice of providing core funds to our Principal Investigators (PIs) through rolling workpackages prepared in conjunction with the Research Strategy Groups and approved by the R&D Committee.
We will introduce a specific funding stream of up to £50,000 per project to support pilot and preliminary studies to help secure external grant funding.
We will establish a programme to support mid-career researchers linked to succession planning, starting with one post in 2016-17.
We will aim to increase the proportion of female group leaders and Principal Investigators, in line with the Athena-SWAN programme for academic centres.